100例宫颈癌患者血清miR-155、miR-501水平及其与术后复发的相关性分析

Correlation of Serum miR-155 and miR-501 Levels with Postoperative Recurrence in 100 Patients with Cervical Cancer

[目的]探讨宫颈癌患者的血清微小核糖核酸(miR)-155、miR-501水平,并分析两者与患者术后复发的关系。[方法]选取2016年1月至2021年3月东南大学医学院附属南京同仁医院收治的最终纳入分析的100例宫颈癌患者,均接受手术治疗,术后接受相应治疗,对患者进行为期1年的随访,记录患者随访期间的复发情况。术前检测患者血清miR-155、miR-501水平和其他相关实验室指标,分析血清miR-155、miR-501水平与患者术后复发的相关性。[结果]经过1年的随访,100例行手术治疗的宫颈癌患者中,有18例出现复发,复发率为18.00%。复发组患者HPV持续阳性比例高于未复发组,且血清SCC-Ag、CA125、miR-155相对表达量和miR-501相对表达量均高于未复发组,差异均有统计学意义(P<0.05)。Cox回归分析结果显示,HPV持续阳性、血清SCCAg、CA125、miR-155相对表达量和miR-501相对表达量与宫颈癌患者术后复发有关(P<0.05)。受试者工作特征(ROC)曲线显示,血清SCC-Ag、CA125、miR-155、miR-501单独及联合预测宫颈癌患者术后复发的AUC均>0.7,有一定预测价值,且以联合预测的价值最好;经决策曲线显示,在阈值0.16~0.50、0.59~0.61、0.77~0.87范围内,血清miR-155、miR-501联合检测的预测模型预测宫颈癌患者术后复发的净收益率优于单纯血清miR-155或miR-501检测。[结论]宫颈癌患者血清miR-155、miR-501水平与术后复发相关,可用于患者术后复发的辅助评估。

[Objective]To investigate the correlation of serum microRNA(miR)-155 and miR-501 levels with postoperative recurrence in patients with cervical cancer. [Methods]One hundred patients with cervical cancer treated in Nanjing Tongren Hospital from January 2016 to March 2021 were enrolled in the study. All patients received surgery and postoperative treatment. The patients were followed up for1 year, and the recurrence during the follow-up period was recorded. Serum miR-155, miR-501 and other laboratory indicators were detected before operation, and the correlation of serum miR-155 and miR-501 levels with postoperative recurrence was analyzed. [Results]After one-year follow-up, the postoperative recurrence occurred in 18 patients with a recurrence rate of 18.00%. The proportion of HPV persistent positive in the recurrent group was higher than that in the non-recurrent group, and the relative expression of serum SCC-Ag, CA125, miR-155 and miR-501 were higher than that in the nonrecurrent group(P<0.05). Cox regression analysis showed that the constantly positive HPV, positive expression of serum SCC-Ag, CA125, miR-155 and miR-501 were related to the postoperative recurrence of patients with cervical cancer(P<0.05). The receiver operating characteristic(ROC) curve showed that the AUCs of serum miR-155 and/or miR-501 in predicting postoperative recurrence were >0.7. The decision curve showed that within the threshold range of 0.16~0.50, 0.59~0.61 and 0.77~0.87, the net benefit rate of prediction model combined with serum miR-155 and miR-501 in predicting postoperative recurrence was better than serum miR-155 or miR-501 alone. [Conclusion]The expression of serum miR-155 and miR-501 is closely related to postoperative recurrence, which may be used for evaluating the risk of postoperative recurrence in patients with cervical cancer.